Interestingly, the sole patient found to be a “double carrier” of the POT1 and MITF variants had an extremely high recurrence rate of melanoma (reporting 10 different resections over the years), possibly reflecting an additive/synergistic effect of the two variants. This evidence concerns the gene MITF and melanoma.